TY - JOUR
T1 - Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder
T2 - A 3-month, prospective, observational study
AU - Harada, Eiji
AU - Satoi, Yoichi
AU - Kuga, Atsushi
AU - Tokuoka, Hirofumi
AU - Kikuchi, Toshiaki
AU - Watanabe, Koichiro
AU - Alev, Levent
AU - Mimura, Masaru
N1 - Funding Information:
The authors are deeply grateful to the primary investigators, sub-investigators, and staff at the 27 study sites, and all the patients who participated in this study. Medical writing assistance was provided by Hirofumi Yamaguchi, PhD, of CMIC Co., Ltd., funded by Eli Lilly Japan K.K. Additional medical writing assistance was provided by Julie Monk, PhD, CMPP and Serina Stretton, PhD, CMPP of ProScribe – Envision Pharma Group, and was funded by Eli Lilly Japan K.K. This study was sponsored by Eli Lilly Japan K.K. and conducted by CMIC Co., Ltd. under contract to Eli Lilly Japan K.K.
Publisher Copyright:
© 2017 Harada et al.
PY - 2017/9/19
Y1 - 2017/9/19
N2 - Purpose: To investigate associations among depression severity, painful physical symptoms (PPS), and social and occupational functioning impairment in patients with major depressive disorder (MDD) who had achieved complete remission (CR) or partial remission (PR) after acute treatment. Patients and methods: This was a 12-week, multicenter, prospective, observational study. Patients with MDD treated with an antidepressant medication for the previous 12 weeks (±3 weeks) who had achieved CR (defined as a 17-item Hamilton Rating Scale for Depression [HAM-D17] score ≤7) or PR (HAM-D17 score ≥8 and ≤18) were enrolled. Depression severity, PPS, and impairment in social and occupational functioning were assessed using the HAM-D17, the Brief Pain Inventory (Short Form) (BPI-SF), and the Social and Occupational Functioning Assessment Scale (SOFAS), respectively, at enrollment (Week 12) and after 12 weeks (Week 24). Results: Overall, 323 Japanese patients with MDD were enrolled (CR n=158, PR n=165) and 288 patients completed the study (CR n=139, PR n=149). HAM-D17 and SOFAS scores were strongly and negatively correlated at enrollment (Week 12; P<0.0001) and Week 24 (P<0.0001). A weak negative correlation between the BPI-SF and SOFAS was observed at Week 24 (P=0.0011), but not at enrollment (P=0.164). Remission status at enrollment (CR or PR) was associated with achieving normal social and occupational functioning (SOFAS score ≥80) at Week 24 in patients who had not achieved normal social and occupational functioning (SOFAS score <80) at enrollment (CR vs PR, OR=0.05 [95% CIs 0.01-0.18], P<0.0001). A greater proportion of patients with CR and no PPS at enrollment achieved SOFAS scores ≥80 at Week 24 than those with CR and PPS. Conclusion: Our results suggest that treating both depressive symptoms and PPS is important for achieving a normal level of functioning on a long-term basis in patients with MDD.
AB - Purpose: To investigate associations among depression severity, painful physical symptoms (PPS), and social and occupational functioning impairment in patients with major depressive disorder (MDD) who had achieved complete remission (CR) or partial remission (PR) after acute treatment. Patients and methods: This was a 12-week, multicenter, prospective, observational study. Patients with MDD treated with an antidepressant medication for the previous 12 weeks (±3 weeks) who had achieved CR (defined as a 17-item Hamilton Rating Scale for Depression [HAM-D17] score ≤7) or PR (HAM-D17 score ≥8 and ≤18) were enrolled. Depression severity, PPS, and impairment in social and occupational functioning were assessed using the HAM-D17, the Brief Pain Inventory (Short Form) (BPI-SF), and the Social and Occupational Functioning Assessment Scale (SOFAS), respectively, at enrollment (Week 12) and after 12 weeks (Week 24). Results: Overall, 323 Japanese patients with MDD were enrolled (CR n=158, PR n=165) and 288 patients completed the study (CR n=139, PR n=149). HAM-D17 and SOFAS scores were strongly and negatively correlated at enrollment (Week 12; P<0.0001) and Week 24 (P<0.0001). A weak negative correlation between the BPI-SF and SOFAS was observed at Week 24 (P=0.0011), but not at enrollment (P=0.164). Remission status at enrollment (CR or PR) was associated with achieving normal social and occupational functioning (SOFAS score ≥80) at Week 24 in patients who had not achieved normal social and occupational functioning (SOFAS score <80) at enrollment (CR vs PR, OR=0.05 [95% CIs 0.01-0.18], P<0.0001). A greater proportion of patients with CR and no PPS at enrollment achieved SOFAS scores ≥80 at Week 24 than those with CR and PPS. Conclusion: Our results suggest that treating both depressive symptoms and PPS is important for achieving a normal level of functioning on a long-term basis in patients with MDD.
KW - Depression
KW - Major depressive disorder
KW - Painful physical symptoms
KW - Remission
KW - Social/occupational functioning
UR - http://www.scopus.com/inward/record.url?scp=85030241602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030241602&partnerID=8YFLogxK
U2 - 10.2147/NDT.S134566
DO - 10.2147/NDT.S134566
M3 - Article
AN - SCOPUS:85030241602
SN - 1176-6328
VL - 13
SP - 2437
EP - 2445
JO - Neuropsychiatric Disease and Treatment
JF - Neuropsychiatric Disease and Treatment
ER -
